Mode
Text Size
Log in / Sign up

Digital chest radiography with CAD shows variable sensitivity for asymptomatic tuberculosis in South African adults

Digital chest radiography with CAD shows variable sensitivity for asymptomatic tuberculosis in South…
Photo by Ayanda Kunene / Unsplash
Key Takeaway
Note that dCXR with CAD sensitivity for asymptomatic TB fell below WHO targets in this South African cohort.

This cohort study included 1353 adults aged 18 years or older in a community-based screening cohort and a facility-based triage cohort in South Africa. The intervention involved digital chest radiography (dCXR) read by blinded human readers and qXR CAD using a 0.5 threshold from Qure.AI, India. The comparator was symptomatic tuberculosis in the triage cohort. Outcomes measured included sensitivity and specificity for asymptomatic and symptomatic tuberculosis.

In the screening cohort, 48 cases (5.4%) were microbiologically confirmed tuberculosis, 9 cases (19%) were symptomatic tuberculosis, and 39 cases (81%) were asymptomatic tuberculosis. In the triage cohort, 116 cases (24.8%) were microbiologically confirmed tuberculosis. Human reader sensitivity for asymptomatic tuberculosis was 56.4% with a 95% confidence interval of -2.9 to -29.1. Human reader sensitivity for symptomatic tuberculosis was 72.4%.

Specificity for asymptomatic tuberculosis was 94.1% with human readers and 89.3% with qXR CAD. Specificity for symptomatic tuberculosis was 81.2% with human readers and 73.5% with qXR CAD. The study did not report adverse events, serious adverse events, discontinuations, or tolerability data. A key limitation is that neither human reader nor qXR CAD evaluation met WHO targets for a tuberculosis screening test, which require 90% sensitivity and 80% specificity.

The World Health Organization recommends digital chest radiography with computer-aided detection for tuberculosis screening of individuals older than 15 years of age. This study suggests that current dCXR and CAD performance in this setting may not fully align with those global screening targets.

Study Details

Study typeCohort
Sample sizen = 1,353
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Background The World Health Organisation (WHO) recommends digital chest radiography (dCXR) with computer-aided detection (CAD) for tuberculosis (TB) screening of individuals >15 years of age. Methodology Adults (18 years or older) were enrolled (March 2021-December 2022) in South Africa into a community-based Screening Cohort (household contacts) and a facility-based Triage Cohort (symptomatic clinic attendees). Microbiologically-confirmed pulmonary TB required positive sputum culture and/or Xpert Ultra. Asymptomatic TB was diagnosed in participants without TB symptoms. dCXR were read by blinded human readers and qXR CAD (0.5 threshold; Qure.AI, India). Results dCXR from 1,353 participants (886 Screening Cohort; 467 Triage Cohort) were analysed. Microbiologically-confirmed TB occurred in 48 (5.4%) Screening Cohort [9 symptomatic (19%) and 39 asymptomatic (81%)]; and 116 (24.8%) Triage Cohort (all symptomatic) participants. dCXR sensitivity (human readers) for asymptomatic TB in the Screening Cohort was 56.4%, vs. 72.4% for symptomatic TB in the Triage Cohort (difference -16%; 95%CI -2.9 to -29.1); with specificities 94.1% and 81.2%, respectively. Corresponding qXR CAD sensitivities were 69.2% vs. 83.6% (difference -14.4%; 95%CI -26 to -2.8), with specificities 89.3% and 73.5%, respectively. The difference in dCXR sensitivity and specificity for asymptomatic TB between qXR CAD and human readers was 12.8% (95%CI -0.48 to 26.1) and -4.8% (95%CI -12.4 to 28.2), respectively. Conclusion Sensitivity of community-based dCXR screening for microbiologically-confirmed asymptomatic TB among household contacts was lower than for facility-based triage of symptomatic TB, but approached 70% with CAD. Neither human reader nor qXR CAD evaluation met WHO targets for a TB screening test (90% sensitivity; 80% specificity).
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.